Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia.

Trial Profile

Study of Pitavastatin Vs. Simvastatin (Following Up-Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2011

At a glance

  • Drugs Pitavastatin; Simvastatin
  • Indications Dyslipidaemias; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Kowa Pharmaceutical
  • Most Recent Events

    • 01 Sep 2009 According to a Kowa Pharmaceutical media release, the company received FDA approval of pitavastatin for the treatment of hypercholesterolemia and combined dyslipidemia in August 2009 and is expected to launch in the US in the first quarter of 2010.
    • 01 Sep 2009 Kowa Pharmaceuticals filed in Europe in August 2008 using the decentralised authorisation procedure, according to a Kowa Pharmaceuticals media release.
    • 21 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top